Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 67

Sort by

Sort Order Select

Journal Articles

Sinusoidal Obstruction Syndrome in Children with CD22+ B-Cell Precursors Acute Lymphoblastic Leukemia (BCP-ALL) Treated with Inotuzumab Ozogamicin in Trial ITCC-059: Risk Factors and Outcomes

Blood (2024) 144 (Supplement 1): 310.

https://doi.org/10.1182/blood-2024-193946

Published: 2024

Journal Articles

A Reduced Daunorubicin Dose during Induction Is Equally Effective As Standard Dose in Children with Acute Lymphoblastic Leukemia (ALL) and Favorable Prognostic Features: Long-Term Results of the Phase 3 Trial AIEOP-BFM ALL 2009

Blood (2024) 144 (Supplement 1): 309.

https://doi.org/10.1182/blood-2024-204943

Published: 2024

Journal Articles

Results in Pediatric T-ALL Patients Treated in Trial AIEOP-BFM ALL 2009: Exploring Prognostic Factors in the Context of Modern Risk Adapted Therapy

Blood (2024) 144 (Supplement 1): 730.

https://doi.org/10.1182/blood-2024-201936

Published: 2024

Journal Articles

Frequency and Early Prognostic Significance of Gene-Class Fusions Identified By RNA-Seq in Children and Adolescent with T-Cell Acute Lymphoblastic Leukemia Enrolled on AIEOP-BFM ALL 2017 Study

Blood (2024) 144 (Supplement 1): 4217.

https://doi.org/10.1182/blood-2024-207345

Published: 2024

Journal Articles

Crebbp Mutations Are Associated with Slow Minimal Residual Response to Upfront Induction Chemotherapy in Pediatric High-Hyperdiploid B-Cell Precursor Acute Lymphoblastic Leukemia Treated in the AIEOP-BFM ALL 2009 Protocol

Giacomo Gotti, Daniela Silvestri, Grazia Fazio, Chiara Palmi, Valentino Conter, Maria Grazia Valsecchi, Carmelo Rizzari, Barbara Buldini, Franco Locatelli, Andrea Biondi, Giovanni Cazzaniga

Blood (2023) 142 (Supplement 1): 4344.

https://doi.org/10.1182/blood-2023-187833

Published: 2023

Journal Articles

Early Post-Infusion Clearance of High-Dose Methotrexate Predicts Delayed Methotrexate Elimination and Acute Kidney Injury

Carmelo Rizzari, Nicolás Tentoni, Ryan Combs, Jennifer Lowe, Miriam Hwang, Thais Murciano, María Dolores Aumente, Teresa López-Viñau López, Scott C. Howard

Blood (2023) 142 (Supplement 1): 3763.

https://doi.org/10.1182/blood-2023-182052

Published: 2023

Journal Articles

Pediatric Patients with High-Risk B-Cell ALL in First Complete Remission May Benefit from Less Toxic Immunotherapy with Blinatumomab - Results from Randomized Controlled Phase 3 Trial AIEOP-BFM ALL 2017

Blood (2023) 142 (Supplement 1): 825.

https://doi.org/10.1182/blood-2023-181524

Published: 2023

Journal Articles

Final Results of the AIEOP (Associazione Italiana Ematologia/Oncologia Pediatrica) AML 2013 Prospective Randomized Trial in Childhood Acute Myeloid Leukemia (AML)

Franco Locatelli, Barbara Buldini, Martina Pigazzi, Carmelo Rizzari, Rosanna Cuccurullo, Franca Fagioli, Manuela Tumino, Luca Lo Nigro, Maria Giuseppina Cefalo, Luisa Strocchio, Marco Zecca, Marco Becilli, Andrea Pession, Nicola Santoro, Concetta Micalizzi, Riccardo Masetti, Pietro Merli

Blood (2023) 142 (Supplement 1): 728.

https://doi.org/10.1182/blood-2023-188682

Published: 2023

Journal Articles

Prognostic Role of Molecular MRD Variations during Treatment of Pediatric AML: A Retrospective AIEOP AML2013/01 Study

Martina Pigazzi, Maddalena Benetton, Pietro Merli, Rosanna Cuccurullo, Katia Polato, Pamela Scarparo, Manuela Tumino, Simone Cesaro, Rosa Maria Mura, Concetta Micalizzi, Claudia Tregnago, Carmelo Rizzari, Marco Zecca, Barbara Buldini, Franco Locatelli

Blood (2023) 142 (Supplement 1): 422.

https://doi.org/10.1182/blood-2023-186918

Published: 2023

Journal Articles

Characterization of the Molecular Landscape of Pediatric Acute Myeloid Leukemia: A Retrospective AIEOP AML2013/01 Study

Maddalena Benetton, Pietro Merli, Nicola Santoro, Luca Lo Nigro, Claudia Tregnago, Ambra Da Ros, Katia Polato, Veronica Zampieri, Barbara Michielotto, Samuela Francescato, Anna Leszl, Riccardo Masetti, Barbara Buldini, Alessandra Biffi, Franca Fagioli, Carmelo Rizzari, Franco Locatelli, Martina Pigazzi

Blood (2023) 142 (Supplement 1): 1580.

https://doi.org/10.1182/blood-2023-186458

Published: 2023

Journal Articles

Plasma S-Evs Mirnas in Pediatric B Lineage Leukemia: Transforming Factors of Bone Marrow Niche

Alice Cani, Carlotta Caterina Damanti, Federica Lovisa, Enrico Gaffo, Giulia Borile, Elisa Carraro, Pina Fusco, Elena Varotto, Stefania Bortoluzzi, Alessandra Biffi, Barbara Buldini, Carmelo Rizzari, Marta Pillon, Lara Mussolin, Silvia Bresolin

Blood (2023) 142 (Supplement 1): 4081.

https://doi.org/10.1182/blood-2023-188680

Published: 2023

Journal Articles

Activin-a Increases B-Cell Acute Lymphoblastic Leukemia (B-ALL) Vesiculation and Modifies the Micro-RNA Cargo: Special Focus on MiR-491-5p

Eugenia Licari, Giulia Cricrì, Francesca Raimondo, Alice Martina Giussani, Marina Pitto, Carmelo Rizzari, Andrea Biondi, Valentina Bollati, Erica Dander, Giovanna D'Amico

Blood (2023) 142 (Supplement 1): 5715.

https://doi.org/10.1182/blood-2023-185904

Published: 2023

Journal Articles

Emapalumab, a Fully Human Anti-Interferon Gamma Monoclonal Antibody, in Pediatric Patients with Primary Hemophagocytic Lymphohistiocytosis: Long-Term Follow-up of a Phase 2/3 Study

Michael B. Jordan, Carl Allen, Anupama Rao, Carmelo Rizzari, Simone Cesaro, Maria Caterina Putti, Julian Sevilla, Cristina de Min, Maria Ballabio, Veronica Asnaghi, Anna Stoltenberg, Radmila Kanceva, Franco Locatelli

Blood (2023) 142 (Supplement 1): 1174.

https://doi.org/10.1182/blood-2023-179362

Published: 2023

Journal Articles

Inotuzumab Ozogamicin (InO) Combined with UKALL-R3 Modified Chemotherapy in Pediatric Patients with B-Cell Precursor CD22+ Acute Lymphoblastic Leukemia (BCP-ALL) - Results from the ITCC-059 Phase 1B Trial

Blood (2022) 140 (Supplement 1): 8976–8978.

https://doi.org/10.1182/blood-2022-163056

Published: 2022

Journal Articles

ALL-REZ BFM 2002 Is Associated with Improved Outcome as Compared to ALL-R3 Strategy in Children with Standard Risk Isolated CNS Relapse of Acute Lymphoblastic Leukemia, while Maintaining Comparable Efficacy in Patients with Bone Marrow Relapse. Results of the Multi-National, Multi-Center Trial IntReALL SR 2010

Blood (2022) 140 (Supplement 1): 3247–3249.

https://doi.org/10.1182/blood-2022-166234

Published: 2022

Journal Articles

Hypersensitivity Reactions to Native E. coli L-Asparaginase in Children with Acute Lymphoblastic Leukemia May Vary By Treatment Schedule and Type of Glucocorticoid in Induction: Results of Trial ALL-BFM 2000

Blood (2022) 140 (Supplement 1): 11676–11678.

https://doi.org/10.1182/blood-2022-163142

Published: 2022

Journal Articles

Activina: A Key Factor Mediating Chemoresistance in B-Cell Type Acute Lymphoblastic Leukemia

Erica Dander, Alessandra Fallati, Rita Starace, Alice Giussani, Mario Mauri, Rocco Piazza, Carmelo Rizzari, Andrea Biondi, Giovanna D'Amico

Blood (2022) 140 (Supplement 1): 6002–6003.

https://doi.org/10.1182/blood-2022-162216

Published: 2022

Journal Articles

Impact of Additional Intensive L-Asparaginase Therapy during Consolidation Phase for High-Risk Acute Lymphoblastic Leukemia: Results of a Randomized Controlled Trial in the AIEOP-BFM ALL 2009 Protocol

Blood (2022) 140 (Supplement 1): 109–111.

https://doi.org/10.1182/blood-2022-166583

Published: 2022

Journal Articles

Population Pharmacokinetics of Inotuzumab Ozogamicin (InO) As Single Agent in Pediatric Relapsed/Refractory Acute Lymphoblastic Leukemia - Results from the ITCC-059 Phase IA and Phase II Trial

Blood (2022) 140 (Supplement 1): 8845–8847.

https://doi.org/10.1182/blood-2022-165954

Published: 2022

Journal Articles

CD72 Is a Pan-Tumor Antigen Associated with Childhood Acute Leukemia

Barbara Buldini, Giovanni Faggin, Elena Porcù, Pamela Scarparo, Katia Polato, Claudia Tregnago, Elena Varotto, Paolo Rizzardi, Carmelo Rizzari, Franco Locatelli, Alessandra Biffi, Martina Pigazzi

Blood (2022) 140 (Supplement 1): 4974–4975.

https://doi.org/10.1182/blood-2022-169040

Published: 2022

NARROW

Sinusoidal Obstruction Syndrome in Children with CD22+ B-Cell Precursors Acute Lymphoblastic Leukemia (BCP-ALL) Treated with Inotuzumab Ozogamicin in Trial ITCC-059: Risk Factors and Outcomes

A Reduced Daunorubicin Dose during Induction Is Equally Effective As Standard Dose in Children with Acute Lymphoblastic Leukemia (ALL) and Favorable Prognostic Features: Long-Term Results of the Phase 3 Trial AIEOP-BFM ALL 2009

Results in Pediatric T-ALL Patients Treated in Trial AIEOP-BFM ALL 2009: Exploring Prognostic Factors in the Context of Modern Risk Adapted Therapy

Frequency and Early Prognostic Significance of Gene-Class Fusions Identified By RNA-Seq in Children and Adolescent with T-Cell Acute Lymphoblastic Leukemia Enrolled on AIEOP-BFM ALL 2017 Study

Crebbp Mutations Are Associated with Slow Minimal Residual Response to Upfront Induction Chemotherapy in Pediatric High-Hyperdiploid B-Cell Precursor Acute Lymphoblastic Leukemia Treated in the AIEOP-BFM ALL 2009 Protocol

Early Post-Infusion Clearance of High-Dose Methotrexate Predicts Delayed Methotrexate Elimination and Acute Kidney Injury

Pediatric Patients with High-Risk B-Cell ALL in First Complete Remission May Benefit from Less Toxic Immunotherapy with Blinatumomab - Results from Randomized Controlled Phase 3 Trial AIEOP-BFM ALL 2017

Final Results of the AIEOP (Associazione Italiana Ematologia/Oncologia Pediatrica) AML 2013 Prospective Randomized Trial in Childhood Acute Myeloid Leukemia (AML)

Prognostic Role of Molecular MRD Variations during Treatment of Pediatric AML: A Retrospective AIEOP AML2013/01 Study

Characterization of the Molecular Landscape of Pediatric Acute Myeloid Leukemia: A Retrospective AIEOP AML2013/01 Study

Plasma S-Evs Mirnas in Pediatric B Lineage Leukemia: Transforming Factors of Bone Marrow Niche

Activin-a Increases B-Cell Acute Lymphoblastic Leukemia (B-ALL) Vesiculation and Modifies the Micro-RNA Cargo: Special Focus on MiR-491-5p

Emapalumab, a Fully Human Anti-Interferon Gamma Monoclonal Antibody, in Pediatric Patients with Primary Hemophagocytic Lymphohistiocytosis: Long-Term Follow-up of a Phase 2/3 Study

Inotuzumab Ozogamicin (InO) Combined with UKALL-R3 Modified Chemotherapy in Pediatric Patients with B-Cell Precursor CD22+ Acute Lymphoblastic Leukemia (BCP-ALL) - Results from the ITCC-059 Phase 1B Trial

Hypersensitivity Reactions to Native E. coli L-Asparaginase in Children with Acute Lymphoblastic Leukemia May Vary By Treatment Schedule and Type of Glucocorticoid in Induction: Results of Trial ALL-BFM 2000

Activina: A Key Factor Mediating Chemoresistance in B-Cell Type Acute Lymphoblastic Leukemia

Impact of Additional Intensive L-Asparaginase Therapy during Consolidation Phase for High-Risk Acute Lymphoblastic Leukemia: Results of a Randomized Controlled Trial in the AIEOP-BFM ALL 2009 Protocol

Population Pharmacokinetics of Inotuzumab Ozogamicin (InO) As Single Agent in Pediatric Relapsed/Refractory Acute Lymphoblastic Leukemia - Results from the ITCC-059 Phase IA and Phase II Trial

CD72 Is a Pan-Tumor Antigen Associated with Childhood Acute Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only